Modeling postradiation prostate specific antigen level kinetics: Predictors of rising postnadir slope suggest cure in men who remain blocheroically free of prostate carcinoma

Cancer

Volumn 83, Issue 1, 1998, Pages 130-134

  Hanlon, Alexandra L ^a   Moore, Dirk F ^b   Hanks, Gerald E ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Cytokinetics; Prostate carcinoma; Prostate specific antigen; Radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; MODEL; PRIORITY JOURNAL; PROSTATE CARCINOMA; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; HUMANS; KINETICS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0032126498     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980701)83:1<130::AID-CNCR17>3.0.CO;2-Y     Document Type: Article

References (23)

1. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society, 1996.
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yaun JJJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
3. Andriole GE. Serum prostate-specific antigen: the most useful tumor marker. J Clin Oncol 1992;10:1205-7.
4. Zagars GK, Pollack A. The fall and rise of prostate-specific antigen: kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 1993;72: 832-42.
5. Kaplan I, Cox R, Bagshaw M. A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy. Cancer 1992;68:400-5.
6. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992;10:1208-17.
7. Meek AG, Park TL, Oberman E, Wielopolski L. A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1990;19:733-41.
8. Lee W, Hanks G, Hanlon A, Schultheiss T. Rising PSA profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997;15:230-8.
9. Morrell C, Pearson J, Carter H, Brant L. Estimating unknown transition times using a piecewise nonlinear mixed-effects model in mean with prostate cancer. J Am Stat Assoc 1995; 90:45-53.
10. American Joint Committtee on Cancer. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. Philadelphia: J.B. Lippincott, 1992.
11. Hanks GE, Lee WR, Hanlon AL, Hunt M, Kaplan E, Epstein BE, et al. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment PSA ≥ 10 ngm/ml. Int J Radiat Oncol Biol Phys 1996;35:861-8.
12. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam therapy. Washington, DC: International Commission on Radiation Units and Measurements; 1993 ICRU Report No. 50.
13. Littrup PJ, Williams CR, Egglin TK, Kane RA. Determination of prostate volume with transrectal ultrasound for cancer screening. Radiology 1991;179:49-53.
14. Kagawa K, Lee W, Schultheiss T, Hunt M, Shaer A, Hanks G. Initial clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997;38:319-25.
15. Roach M, Faillace-Akazawa P, Malfatti C, Holland J, Hricak H. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1996;35:1011-8.
16. Davidian M, Giltinan D. Nonlinear models for repeated measurement data. New York: Chapman and Hall, 1995.
17. Littell R, Milliken G, Stroup W, Wolfinger R. Nonlinear mixed models. In: SAS System for mixed models. Cary, NC: SAS Institute Inc., 1996:461-89.
18. Beal S, Sheiner L. Estimating population kinetics. Crit Rev Biomed Eng 1982;8:195-222.
19. Sheiner L, Beal S. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm 1985;13:185-201.
20. Svanholm H. Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic specific acid phosphatase. APMIS 1986;94:7-12.
21. Ellis DW, Leffers S, Davies JS, Ng ABP. Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. Am J Clin Pathol 1984;81:279-84.
22. Hanks GE, Perez CA, Kozar M, Asbell SO, Pilepich MV, Pajak TF. PSA confirmation of cure at 10 years of the T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys 1994;30:289-92.
23. Johnstone P, Powell C, Riffenburgh R, Bethel K, Kane C. The fate of 10-year clinically recurrence-free survivors after definitive radiotherapy for T1-3N0M0 prostate cancer. Radiat Oncol Invest 1998;6:103-8.